Navigation Links
Vanda Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 2, 2009
Date:10/28/2009

ROCKVILLE, Md., Oct. 28 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders, today announced it will release results for the quarter ended September 30, 2009, on Monday, November 2, 2009, before the market opens. A full text copy of the release will be disseminated at that time.

Mihael H. Polymeropoulos, M.D., President and Chief Executive Officer, will host a conference call to discuss the results at 10:00 AM ET on Monday, November 2, 2009. Also participating on the call will be Stephanie R. Irish, Acting CFO. To participate in the conference call, dial the appropriate number below shortly before the 10:00 AM start time and ask for the Vanda Pharmaceuticals conference call hosted by Dr. Polymeropoulos.

The teleconference dial-in numbers are as follows:

Domestic callers 1-800-901-5247

International callers 1-617-786-4501

Participant Passcode 46702701

The conference call will be broadcast simultaneously and archived on the Company's Web site, www.vandapharma.com. Investors should go to the Web site at least 15 minutes early to register, download, and install any necessary audio software.

A replay of the call will be available on Monday, November 2, beginning at 1:00 PM ET and will be accessible until Monday, November 9, 2009, at 5:00 PM ET. The replay call-in number is 1-888-286-8010 for domestic callers and 1-617-801-6888 for international callers. The access number is 87052099.

ABOUT VANDA PHARMACEUTICALS INC.:

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com.

SOURCE Vanda Pharmaceuticals Inc.


'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Vanda Pharmaceuticals Announces Date of Annual Meeting of Stockholders
2. Vanda Pharmaceuticals Announces Withdrawal of Director Nominees and Proposal to Liquidate Submitted by Tang Capital
3. Vanda Pharmaceuticals Responds to Announcement and Filing by a Group Led by Tang Capital Partners, LP
4. FDA Accepts Vanda Pharmaceuticals Iloperidone Resubmission and Sets New Action Date
5. Vanda Pharmaceuticals Announces Receipt of Not Approvable Letter From FDA for Iloperidone
6. Vanda Pharmaceuticals to Present at the FBR Capital Markets 12th Annual Spring Investor Conference
7. Vanda Pharmaceuticals Announces that it No Longer Intends to Offer Convertible Senior Notes
8. Vanda Pharmaceuticals VSF-173 Excessive Sleepiness Phase II Clinical Trial Suggests Wake-Promoting Properties
9. Vanda Pharmaceuticals to Announce Third Quarter 2007 Financial Results on November 8, 2007
10. Vanda Pharmaceuticals to Present New Data on Iloperidone at the 2007 American Society of Human Genetics Annual Meeting
11. Vanda Pharmaceuticals to Present at Natixis Bleichroeders Hidden Gems Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... ... November 30, 2016 , ... The Fertility Centers ... as a Cigna Infertility Center of Excellence. The Cigna Center of Excellence recognizes ... an honor to be designated a Cigna Infertility Center of Excellence," said Fertility ...
(Date:11/30/2016)... , ... November 30, 2016 , ... "I hate when ... arm while brushing my teeth," said an inventor from Bridgewater, N.J. "I thought that ... develop this handy device." , He developed the patent-pending DEFLECTOR to prevent saliva and ...
(Date:11/30/2016)... FL (PRWEB) , ... November 30, 2016 , ... ... disorder and mental health treatment has announced the opening of a new eating ... partial hospitalization and intensive outpatient treatment for adults and adolescents, both males and ...
(Date:11/30/2016)... ... November 30, 2016 , ... In recent policy debates, increasing ... public policymakers and system stakeholders in many states. To help them understand this ... Index for Workers’ Compensation, Eighth Edition (MPI-WC) . , “If you are a ...
(Date:11/30/2016)... ... 30, 2016 , ... The Clinical Data Interchange Standards Consortium ... Guidance goes into effect next month. Sponsors whose studies start after December 17, ... Catalog. The current FDA Data Standards Catalog specifies the use of CDISC standards: ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... 2, 2016  UCB is pleased to announce that 12 scientific ... 70 th American Epilepsy Society (AES) Annual Meeting, which ... , USA. 1-12 Data being ... of VIMPAT ® (lacosamide) CV and BRIVIACT ® ... the current state of the union of epilepsy care and ...
(Date:12/2/2016)... , December 2, 2016 The iShares ... past losses following Trump,s victory early in November. Less ... fund managers are now predicting an uptick in M&A ... equities to see how they have fared at the ... ), Amicus Therapeutics Inc. (NASDAQ: FOLD ), ...
(Date:11/30/2016)... -- Research and Markets has announced the addition of ... report to their offering. ... Detachable coil embolization is a minimally ... detachable coil embolization treatment of cerebral aneurysms is less invasive and requires ... in the wall of an artery in the brain. This area bulges ...
Breaking Medicine Technology: